8-K
false570 LEXINGTON AVENUE, 35TH FLOOR10022NEW YORKNY00018039010001803901talk:WarrantsToPurchaseCommonStockMember2022-11-082022-11-080001803901us-gaap:CommonStockMember2022-11-082022-11-0800018039012022-11-082022-11-08

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 8, 2022

 

 

Talkspace, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

Delaware

 

001-39314

 

84-4636604

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 

Address Not Applicable

 

Address Not Applicable

(Address of principal executive offices)

 

(Zip Code)

(212) 284-7206

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common stock, $0.0001 par value per share

 

TALK

 

Nasdaq Global Select Market

Warrants to purchase common stock

 

TALKW

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

 

 


Item 2.02 Results of Operations and Financial Condition.

Talkspace, Inc. (the “Company”) issued a press release on November 8, 2022 announcing its financial results for the third quarter ended September 30, 2022. A copy of the press release issued in connection with this announcement is furnished as Exhibit 99.1 attached hereto.

 

The information in this Item 2.02, including the information contained in Exhibit 99.1 of this Current Report on Form 8-K, is being furnished hereby and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
 

Exhibit

Number

 

Description

99.1

 

Press Release issued by Talkspace, Inc. dated November 8, 2022.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).


 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

 

Talkspace, Inc.

 

 

 

 

Date:

November 8, 2022

By:

/s/ Jennifer Fulk

 

 

 

Jennifer Fulk

Chief Financial Officer

 


EX-99.1

 

Exhibit 99.1

https://cdn.kscope.io/6e7356eb7186659dd0e41a30f8714536-img227085625_0.jpg 

 

Talkspace Reports 2022 Third Quarter and Nine Months Results

Strong acceleration in B2B revenue growth

Added ~9 million eligible lives and 10 new enterprise accounts in the quarter

Meaningful actions taken to reduce operating expense run-rate and drive efficiencies

NEW YORK, November 8, 2022 – Talkspace, Inc. (Nasdaq: TALK), a leading virtual behavioral healthcare company, today reported 2022 third quarter and nine months results as summarized below. All financial results refer to 2022 third quarter or nine months and the related prior-year period unless otherwise stated.

 

 

Three Months

 

 

Nine Months

 

Period ended September 30, 2022

 

Results

 

 

Variance from Prior Year %

 

 

Results

 

 

Variance from Prior Year %

 

(In thousands unless otherwise noted)

 

Unaudited

 

 

 

 

 

Unaudited

 

 

 

 

Number of B2B eligible lives (in millions)

 

 

86.1

 

 

 

52

%

 

 

86.1

 

 

 

52

%

Number of completed B2B sessions

 

 

111.4

 

 

 

56

%

 

 

298.0

 

 

 

55

%

Number of B2C active members 1

 

 

17.9

 

 

 

(36

)%

 

 

17.9

 

 

 

(36

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

Total revenue

 

$

29,332

 

 

 

11

%

 

$

89,326

 

 

 

6

%

Gross profit

 

$

14,595

 

 

 

3

%

 

$

44,163

 

 

 

(13

)%

Gross margin %

 

 

49.8

%

 

(4.0) pts

 

 

 

49.4

%

 

(10.7) pts

 

Operating expenses

 

$

34,446

 

 

 

(13

)%

 

$

106,290

 

 

 

(8

)%

Net loss

 

$

(17,983

)

 

*

 

 

$

(61,365

)

 

 

(47

)%

Adjusted EBITDA 2

 

$

(15,463

)

 

 

26

%

 

$

(50,835

)

 

 

(17

)%

Cash and cash equivalents

 

$

152,639

 

 

 

(32

)%

 

$

152,639

 

 

 

(32

)%

(1) Reflects active members at the end of the period.

(2) Adjusted EBITDA is a non-GAAP financial measure. For a definition of the measure and a reconciliation to the most directly comparable GAAP measure, see “Reconciliation of Non-GAAP Results to GAAP Results.”

* Percentage not meaningful.

 

Our third quarter performance was characterized by a significant acceleration in business-to-business (B2B”) revenue growth, driven by higher penetration of our in-network services and new enterprise client wins, offset by an anticipated decline in business-to-consumer (B2C”) revenue as we continue to optimize consumer marketing spend,” said Chief Financial Officer, Jennifer Fulk. “We are working with renewed emphasis on downsizing our cost base and extracting operating efficiencies, while continuing to focus on our B2B franchise and investing in compelling and profitable growth initiatives.”

Nine Months Key Performance and Financial Metrics

Revenue grew 6% to $89 million, driven by a 72% growth in B2B revenue, partially offset by a 24% decline in B2C revenue. B2B revenue performance was driven by growth in eligible lives and a greater number of completed B2B sessions. B2C revenue declined, as expected, due to our decision to continue to optimize marketing spend.
Gross profit declined 13% to $44 million, and gross margin declined to 49.4%, due primarily to the revenue mix shift toward the B2B business, in line with our strategy, and higher therapist hourly compensation expense.
Net loss was higher compared to the prior period at $61 million as lower marketing spend was offset by higher cost of revenues driven in part by higher therapist-related expenses, and a decrease in gains resulting from the revaluation of warrant liabilities. Adjusted EBITDA loss was $51 million, compared to $43 million in the prior-year period.

 

 


 

Third Quarter 2022 Key Performance and Financial Metrics

 

Revenue grew 11% to $29 million, driven by a reported 117% growth in B2B revenue, partially offset by a 33% decline in B2C revenue.
Gross profit declined 3% to $15 million, and gross margin declined to 49.8%.
Net loss was $18 million, compared to net income of $2 million in the prior-year period, driven primarily by lower marketing spend, offset by higher cost of revenues and a decrease in gains resulting from the revaluation of warrant liabilities. Adjusted EBITDA loss was $15 million, compared to $21 million in the prior-year period.

 

 

Conference Call, Presentation Slides, and Webcast Details

 

The conference call will be available via audio webcast at investors.talkspace.com and can also accessed by dialing (888) 330-2391 for U.S. participants, or +1 (240) 789-2702 for international participants, and referencing participant code 2348878. A replay will be available shortly after the call’s completion and remain available for approximately 90 days.

 

About Talkspace

 

Talkspace (Nasdaq: TALK) is a leading virtual behavioral healthcare company committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall healthcare and should be available to everyone.

 

Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services from self-guided products to individual and couples therapy, in addition to psychiatric treatment and medication management. With Talkspace’s core psychotherapy offering, members are matched with one of thousands of licensed providers across all 50 states and can choose from a variety of subscription plans including video, text or audio chat sessions and/or unlimited text messaging.

 

All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. Talkspace covered approximately 86 million lives at September 30, 2022, through our partnerships with employers, health plans, and paid benefits programs.

 

For more information, visit www.talkspace.com.

 


 

 

 

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking, including statements regarding our financial condition, anticipated financial performance, achieving profitability, business strategy and plans, market opportunity and expansion and objectives of our management for future operations. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast”, “future”, “intend,” “may,” “might”, “opportunity”, “plan,” “possible”, “potential,” “predict,” “project,” “should,” “strategy”, “strive”, “target,” “will,” or “would”, the negative of these words or other similar terms or expressions. The absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many important factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: our history of losses; the rapid evolution of our business and the markets in which we operate; our ability to continue growing at the rates we have historically grown, or at all; the development of the virtual behavioral health market; COVID-19 and its impact on business and economic conditions; a deterioration in general economic conditions as a result of inflation, increased interest rates or otherwise; competition in our industry; and our relationships with affiliated professional entities to provide physician and other professional services. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described under the caption “Risk Factors” in our Annual Report on Form 10-K for the annual period ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on February 25, 2022, and our other documents filed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

 

 

Contacts

‍For Investors:

Jeannine Feyen

Director, Communications

(917) 748-5325

jeannine.feyen@talkspace.com

 

For Media:

SKDK

John Kim

310-997-5963

jkim@skdknick.com


 

 

 

 


 

Talkspace, Inc.

Consolidated Statements of Operations

(Unaudited)

 

 

 

Three Months Ended
September 30,

 

 

Variance

 

 

Nine Months Ended
September 30,

 

 

Variance

 

 

 

2022

 

 

2021

 

 

$

 

 

%

 

 

2022

 

 

2021

 

 

$

 

 

%

 

(in thousands, except percentages, share and per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

B2B revenue

 

$

16,793

 

 

$

7,728

 

 

$

9,065

 

 

 

117.3

 

 

$

45,129

 

 

$

26,213

 

 

$

18,916

 

 

 

72.2

 

B2C revenue

 

 

12,539

 

 

 

18,631

 

 

 

(6,092

)

 

 

(32.7

)

 

 

44,197

 

 

 

58,286

 

 

 

(14,089

)

 

 

(24.2

)

Total revenue

 

 

29,332

 

 

 

26,359

 

 

 

2,973

 

 

 

11.3

 

 

 

89,326

 

 

 

84,499

 

 

 

4,827

 

 

 

5.7

 

Cost of revenues

 

 

14,737

 

 

 

12,187

 

 

 

2,550

 

 

 

20.9

 

 

 

45,163

 

 

 

33,698

 

 

 

11,465

 

 

 

34.0

 

Gross profit

 

 

14,595

 

 

 

14,172

 

 

 

423

 

 

 

3.0

 

 

 

44,163

 

 

 

50,801

 

 

 

(6,638

)

 

 

(13.1

)

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development, net

 

 

6,182

 

 

 

4,278

 

 

 

1,904

 

 

 

44.5

 

 

 

16,793

 

 

 

12,023

 

 

 

4,770

 

 

 

39.7

 

Clinical operations

 

 

2,222

 

 

 

1,896

 

 

 

326

 

 

 

17.2

 

 

 

6,314

 

 

 

5,886

 

 

 

428

 

 

 

7.3

 

Sales and marketing

 

 

18,375

 

 

 

26,431

 

 

 

(8,056

)

 

 

(30.5

)

 

 

58,714

 

 

 

75,125

 

 

 

(16,411

)

 

 

(21.8

)

General and administrative

 

 

7,667

 

 

 

6,794

 

 

 

873

 

 

 

12.8

 

 

 

24,469

 

 

 

23,112

 

 

 

1,357

 

 

 

5.9

 

Total operating expenses

 

 

34,446

 

 

 

39,399

 

 

 

(4,953

)

 

 

(12.6

)

 

 

106,290

 

 

 

116,146

 

 

 

(9,856

)

 

 

(8.5

)

Operating loss

 

 

(19,851

)

 

 

(25,227

)

 

 

5,376

 

 

 

21.3

 

 

 

(62,127

)

 

 

(65,345

)

 

 

3,218

 

 

 

4.9

 

Financial income, net

 

 

1,885

 

 

 

26,743

 

 

 

(24,858

)

 

 

(93.0

)

 

 

889

 

 

 

23,700

 

 

 

(22,811

)

 

 

(96.2

)

(Loss) income before taxes on income

 

 

(17,966

)

 

 

1,516

 

 

 

(19,482

)

 

*

 

 

 

(61,238

)

 

 

(41,645

)

 

 

(19,593

)

 

 

(47.0

)

Taxes on income

 

 

17

 

 

 

11

 

 

 

6

 

 

 

54.5

 

 

 

127

 

 

 

29

 

 

 

98

 

 

 

337.9

 

Net (loss) income

 

$

(17,983

)

 

$

1,505

 

 

$

(19,488

)

 

*

 

 

$

(61,365

)

 

$

(41,674

)

 

$

(19,691

)

 

 

(47.3

)

Net (loss) income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.11

)

 

$

0.01

 

 

$

(0.12

)

 

*

 

 

$

(0.39

)

 

$

(0.64

)

 

$

0.25

 

 

 

39.1

 

Diluted

 

$

(0.11

)

 

$

0.01

 

 

$

(0.12

)

 

*

 

 

$

(0.39

)

 

$

(0.64

)

 

$

0.25

 

 

 

39.1

 

Weighted average number of common shares:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

158,330,684

 

 

 

152,267,870

 

 

 

 

 

 

 

 

 

156,056,900

 

 

 

64,638,182

 

 

 

 

 

 

 

Diluted

 

 

158,330,684

 

 

 

165,179,012

 

 

 

 

 

 

 

 

 

156,056,900

 

 

 

64,638,182

 

 

 

 

 

 

 

* Percentage not meaningful

 

 


 

Talkspace, Inc.

Consolidated Balance Sheets

 

 

 

September 30, 2022

 

 

December 31, 2021

 

(in thousands)

 

(Unaudited)

 

 

 

 

ASSETS

 

 

 

 



 

CURRENT ASSETS:

 



 

 



 

Cash and cash equivalents

 

$

152,639

 

 

$

198,256

 

Accounts receivable, net

 

 

8,692

 

 

 

5,512

 

Other current assets

 

 

4,606

 

 

 

9,562

 

Total current assets

 

 

165,937

 

 

 

213,330

 

Property and equipment, net

 

 

845

 

 

 

624

 

Intangible assets, net

 

 

2,714

 

 

 

3,436

 

Goodwill

 

 

6,134

 

 

 

6,134

 

Other long-term assets

 

 

 

 

 

82

 

Total assets

 

$

175,630

 

 

$

223,606

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 



 

 



 

CURRENT LIABILITIES:

 



 

 



 

Accounts payable

 

$

10,360

 

 

$

7,429

 

Deferred revenues

 

 

5,458

 

 

 

7,186

 

Accrued expenses and other current liabilities

 

 

13,206

 

 

 

12,562

 

Total current liabilities

 

 

29,024

 

 

 

27,177

 

Warrant liabilities

 

 

3,649

 

 

 

4,070

 

Other long-term liabilities

 

 

288

 

 

 

86

 

Total liabilities

 

 

32,961

 

 

 

31,333

 

Commitments and contingencies

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY:

 



 

 



 

Common stock

 

 

15

 

 

 

15

 

Additional paid-in capital

 

 

375,549

 

 

 

363,788

 

Accumulated deficit

 

 

(232,895

)

 

 

(171,530

)

Total stockholders’ equity

 

 

142,669

 

 

 

192,273

 

Total liabilities and stockholders’ equity

 

$

175,630

 

 

$

223,606

 

 

 


 

Talkspace, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

Nine Months Ended
September 30,

 

(in thousands)

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(61,365

)

 

$

(41,674

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

1,006

 

 

 

1,458

 

Amortization of debt issuance cost

 

 

 

 

 

175

 

Stock-based compensation

 

 

9,386

 

 

 

20,584

 

Warrant issue costs and change in fair value

 

 

(421

)

 

 

(23,842

)

(Increase) decrease in accounts receivable, net

 

 

(3,180

)

 

 

596

 

Decrease (increase) in other current assets

 

 

4,848

 

 

 

(8,515

)

Increase in accounts payable

 

 

2,931

 

 

 

7,113

 

(Decrease) increase in deferred revenues

 

 

(1,728

)

 

 

3,130

 

Increase (decrease) in accrued expenses and other current liabilities

 

 

1,465

 

 

 

(134

)

Increase in other long-term liabilities

 

 

202

 

 

 

 

Net cash used in operating activities

 

 

(46,856

)

 

 

(41,109

)

Cash flows from investing activities:

 

 

 

 

 

 

Purchase of property and equipment

 

 

(254

)

 

 

(622

)

Net cash used in investing activities

 

 

(254

)

 

 

(622

)

Cash flows from financing activities:

 

 

 

 

 

 

(Payments) proceeds from reverse capitalization, net of transaction costs

 

 

(645

)

 

 

249,428

 

Proceeds from borrowings

 

 

 

 

 

6,000

 

Repayment of borrowings

 

 

 

 

 

(6,000

)

Payment of debt issuance cost

 

 

 

 

 

(50

)

Proceeds from exercise of stock options

 

 

2,696

 

 

 

1,970

 

Payments for employee taxes withheld related to vested stock-based awards

 

 

(558

)

 

 

 

Net cash provided by financing activities

 

 

1,493

 

 

 

251,348

 

Net (decrease) increase in cash and cash equivalents

 

 

(45,617

)

 

 

209,617

 

Cash and cash equivalents at the beginning of the period

 

 

198,256

 

 

 

13,248

 

Cash and cash equivalents at the end of the period

 

$

152,639

 

 

$

222,865

 

 

 


 

 

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with GAAP, we believe adjusted EBITDA, a non-GAAP measure, is useful in evaluating our operating performance. We use adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. We believe that the use of adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measure as a tool for comparison. A reconciliation is provided below for this non-GAAP financial measure to net (loss) income, the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review our GAAP financial measure and the reconciliation of our non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities.

We calculate adjusted EBITDA as net (loss) income adjusted to exclude (i) interest and other expenses (income), net, (ii) tax benefit and expense, (iii) depreciation and amortization (iv) stock-based compensation expense and (v) certain non-recurring expenses, where applicable.

Talkspace, Inc.

Reconciliation of Non-GAAP Results to GAAP Results

(Unaudited)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

(in thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net (loss) income

 

$

(17,983

)

 

$

1,505

 

 

$

(61,365

)

 

$

(41,674

)

Add:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

309

 

 

 

503

 

 

 

1,006

 

 

 

1,458

 

Financial (income), net (1)

 

 

(1,885

)

 

 

(26,743

)

 

 

(889

)

 

 

(23,700

)

Taxes on income

 

 

17

 

 

 

11

 

 

 

127

 

 

 

29

 

Stock-based compensation

 

 

3,179

 

 

 

3,875

 

 

 

9,386

 

 

 

20,584

 

Non-recurring expenses (2)

 

 

900

 

 

 

 

 

 

900

 

 

 

 

Adjusted EBITDA

 

$

(15,463

)

 

$

(20,849

)

 

$

(50,835

)

 

$

(43,303

)

 

1) For the three and nine months ended September 30, 2022, financial income, net, primarily consisted of $1.6 million and $0.4 million, respectively, in gains resulting from the revaluation of warrant liabilities.

For the three months ended September 30, 2021, financial income, net primarily consisted of $26.9 million in gains resulting from the revaluation of warrant liabilities. For the nine months ended September 30, 2021, financial income, net primarily consisted of $28.3 million in gains resulting from the revaluation of warrant liabilities, partially offset by $4.2 million in warrant issuance costs in connection with the Closing of the Business Combination.

 

2) For the three and nine months ended September 30, 2022, non-recurring expenses consisted of $0.6 million in legal fees and $0.3 million in general and administrative expenses.